

PARTNERSHIP FOR
clean competition

ANNUAL REPORT 2016



CLEANCOMPETITION.ORG

TABLE OF CONTENTS

3	A Message from the PCC
5	Board of Governors
6	Staff and Officers
7	Scientific Advisory Board
9	A Year in Review
16	Financial Overview

WHERE WE ARE NOW

A MESSAGE TO OUR STAKEHOLDERS

2016 marked a year of tremendous growth for the PCC, made possible by the support and commitment of our incredible sponsors, board members, scientists, and anti-doping allies around the world.

Not only did the PCC award global scientists nearly \$3M USD to enhance and evolve anti-doping technology (a 36% increase from 2015), but for the first time the PCC funded more projects outside the US than within it, with 57% of projects being led by international investigators. This shift securely positions the PCC as the premier funder of anti-doping research on a global scale.

Moreover, the first HgH Biomarkers test was implemented into labs in late 2016, thanks to the dedication of the PCC's IGF-1 Working Group. The Working Group consolidated the acumen of scientists from six distinct labs, a dynamic which facilitated not only the most sophisticated HgH testing protocol to date, but also the interlaboratory precision key to consistent results between laboratories.

The PCC also grew in terms of both contributor staff and support resources. The hiring of Stakeholder Engagement Manager Jenna Celmer doubled the PCC's operational staff member count, and allowed for the creation of more robust and consistent outreach efforts designed to keep stakeholders informed of PCC activities and successes.

Finally, the PCC is pleased to announce the renewed sponsorship commitments of both the PGA TOUR and the National Hockey League, which highlights the dedication of both leagues to protecting the health and integrity of their athletes.

As we look towards 2017 and beyond, the PCC remains committed to actively fostering and supporting the scientific talent that so powerfully impacts PED detection and deterrence for all sports, at all levels of play.

*Sincerely,
Michael Pearlmutter*

PARTNERSHIP FOR
clean competition

LEADERSHIP

BOARD OF GOVERNORS



Dan Halem

MAJOR LEAGUE BASEBALL



Nina Kemppe

UNITED STATES OLYMPIC COMMITTEE



Travis Tygart

UNITED STATES ANTI-DOPING AGENCY



Adolpho Birch III

NATIONAL FOOTBALL LEAGUE

Board Chair*

Major League Baseball's Chief Legal Officer, Mr. Halem oversees all collective bargaining issues with the MLB Players Association, including the annual updates to Joint Drug Prevention and Treatment Program. Mr. Halem also works closely with club management officials and helps directs the administration of MLB's revenue sharing system, the debt-service rule, the competitive balance tax, the salary arbitration system, and the amateur draft support program. Prior to joining MLB, Mr. Halem was a partner at the law firm of Proskauer Rose, where he represented and counseled the NBA, the WNBA, the NHL, and the New York Jets of the NFL. Mr. Halem graduated from Cornell University's School of Industrial and Labor Relations in 1988 and from Harvard Law School, magna cum laude, in 1991.

*current as of September 2017

Ms Kemppe has served as a member of the USOC's Board of Directors since 2010. A four-time Olympian in the sport of cross country skiing, she has been a long time advocate against doping in sport. She recently served three years on the World Anti-Doping Agency's Athlete Committee, representing the views and rights of athletes worldwide. From 2005 to 2008, she worked directly with the U.S. Anti-Doping Agency and championed the USOC's initial Safe Sport initiative while serving as the USOC Athlete Advisory Committee Vice-Chair of the Anti-Doping Committee. She is currently the President and CEO of the Alaska Community Foundation in Anchorage, Alaska.

Serving as USADA's Chief Executive Officer since September 2007, Travis T. Tygart leads the organization's efforts to preserve the integrity of competition, inspire true sport, and protect the rights of clean athletes. Under Tygart's leadership, some of USADA's most significant efforts to protect athletes' rights have come in the form of international advocacy of clean sport, most recently in relation to the Russian doping scandal, and in the form of major investigations. Working alongside federal authorities, USADA investigated the international steroid bust, Operation Raw Deal, and the international doping conspiracy involving the BALCO laboratory in San Francisco. Tygart also led the investigation into the U.S. Postal Service pro-cycling team doping conspiracy and spearheaded the publication of the Reasoned Decision in the Lance Armstrong case.

Senior Vice President of Labor Policy & League Affairs for the National Football League, Birch oversees the development, administration and enforcement of the League's critical policies respecting the integrity of the game, including those on substances of abuse, performance-enhancing drugs, gambling and criminal misconduct. Mr. Birch also has advanced the League's legislative and political interests, working with federal, state and local officials on key league issues such as youth concussion laws, the league's tax status and the FCC's blackout rule. Prior to joining the NFL, Mr. Birch was in private practice in Houston, Texas. Mr. Birch attended Vanderbilt University Law School as a Patricia Roberts Harris Scholar.

STAFF & OFFICERS



**Michael
Pearlmutter**

EXECUTIVE
DIRECTOR

Michael Pearlmutter was named Executive Director for the Partnership for Clean Competition Research Collaborative in January 2014. In this role, Pearlmutter is responsible for developing, directing, and driving organizational strategy and overseeing daily operations, including managing the organization's \$3M budget, fundraising, business development, grant administration, scientific outreach, and communication with the PCC Board of Governors and Scientific Advisory Board.



**Jenna
Celmer**

STAKEHOLDER
ENGAGEMENT MANAGER

Ms. Celmer joined the PCC as Stakeholder Engagement Manager in March of 2016 to provide dedicated outreach and communications services to the PCC's numerous sponsors, researchers, and collaborators. In this role Celmer supports the promotion, growth and advancement of PCC programming and partnerships through implementing strategic engagement initiatives, creative marketing efforts, and mission-driven support mechanisms for the anti-doping community.



**Christopher
McCleary**

UNITED STATES
OLYMPIC COMMITTEE

In his current role as the general counsel for the United States Olympic Committee, Mr. McCleary is responsible for all legal issues faced by the organization and all necessary functions as corporate secretary for the USOC Board of Directors. Additionally, he serves as the organization's ethics officer, coordinating with the USOC Ethics Committee, and oversees the USOC's partnerships with the World Anti-Doping Agency, U.S. Anti-Doping Agency, and Partnership for Clean Competition. McCleary joined the USOC from Visa Inc., where he served eight years as the senior vice president and senior associate general counsel of global brand and client management, in which he led the company's worldwide legal operations in marketing, sponsorships, intellectual property, and client licensing.



**Kevin
Manara**

NATIONAL
FOOTBALL LEAGUE

Kevin Manara serves as Senior Labor Relations Counsel for the NFL. His responsibilities include the administration of the League's collective bargaining agreement with its players, as well as enforcement of the League's policies on performance-enhancing substances, personal conduct and substances of abuse. Kevin represents NFL clubs in grievances filed by players under the CBA, prosecutes appeals of discipline imposed under League policies and advises clubs on a variety of contractual, disciplinary and other labor-related matters. Kevin was a member of the NFL Management Council's bargaining team during negotiations that resulted in the 2011 CBA and the 2014 drug and steroid policies. Prior to joining the NFL, Kevin was an associate in the Labor & Employment department at Proskauer Rose. Kevin graduated from Johns Hopkins University, where he played varsity football, and earned his law degree with honors from New York Law School.

SCIENTIFIC ADVISORY BOARD



LARRY BOWERS, PH.D.

As USADA'S Chief Science Officer from 2000 to 2016, Dr. Bowers provided leadership and scientific support for USADA's research sample collection planning, results management, arbitration, education programs, and the prestigious USADA Annual Symposium. Past Associate Editor (Drug Testing and Toxicology) for the journal, Clinical Chemistry, Dr. Bowers was the deputy director of the Athletic Drug Testing Laboratory for the 1996 Olympic Games, and has served on several scientific organizations Board of Directors. Dr. Bowers is currently a member of the World Anti-Doping Agency (WADA) Laboratory Accreditation Working Group.



BRYAN S. FINKLE, PH.D.

Former Director of the Center for Human Toxicology at the University of Utah, and the Department of Pharmacology Sciences at Genentech, Inc. South San Francisco, Dr. Finkle is Chief Consulting Toxicologist to the National Football League, consultant to the World and U.S. Anti-Doping Agencies, President and Chairman of the Board for the Sports Medicine Research and Testing Laboratory, and serves on the Board of the NFL Health Foundation.



GARY GREEN, M.D.

Gary Green, MD, was appointed Medical Director for Major League Baseball in 2010 and has served as MLB's consultant on anabolic steroids and performance-enhancing substances since 2003. He also serves as research director for MLB. He is a fellow in the American College of Physicians and American College of Sports Medicine and a Clinical professor in the UCLA School of Medicine in the Division of Sports Medicine, Dr. Green is the head team physician for Pepperdine University and serves on the California Interscholastic Federation Medical Advisory Committee. He is also on review boards for USADA for adverse analytical findings and therapeutic use exemptions.



GERHARD BAUMANN, M.D.

Past Chief of Endocrinology and Metabolism at the Veterans Administration Lakeside Medical Center and the Associate Director of the Northwestern University General Clinical Research Center, Dr. Baumann is a Professor of Medicine Emeritus at Northwestern University. Dr. Baumann discovered the growth hormone binding protein, the circulating ectodomain, of the growth hormone receptor.



ALVIN M. MATSUMOTO, M.D.

Dr. Matsumoto is a Professor of Medicine in the Division of Gerontology & Geriatric Medicine at the University of Washington, School of Medicine in Seattle. He is Director of the Clinical Research Unit, Associate Director of the Geriatric Research, Education & Clinical Center, Acting Chief of the Gerontology Section and an Attending Physician in Internal Medicine, Geriatric Medicine and Endocrinology & Metabolism at the Department of Veterans Affairs Puget Sound Health Care System. He is Chair of the Laureate Awards Committee of The Endocrine Society, Co-Chair of the Partnership for the Accurate Testing of Hormones (PATH), serves as an Editor for the Journal of Clinical Endocrinology & Metabolism and has served on USADA's Research Policy Advisory Committee.

SCIENTIFIC ADVISORY BOARD



MICHAEL M. SAWKA, PH.D.

Chief Scientific Officer of Environmental Physiology and Hydration Associates, Adjunct Professor of Biological Sciences at Georgia Institute of Technology and past Chief of Thermal and Mountain Medicine at the US Army Research Institute of Environmental Medicine, Dr. Sawka is an expert in environmental physiology (heat, cold, high-altitude), blood volume control, fluid/ electrolyte balance, temperature regulation, and exercise physiology.



LAWRENCE SILVERMAN, PH.D.

Emeritus Professor of Pathology at the University of Virginia, Dr. Silverman also served as Director of the Molecular Diagnostics, Clinical Genomics, and Immunology Laboratories at the University of Virginia, as well as Director of the Division of Molecular Pathology, and Director of the Immunochemistry/Molecular Genetics Laboratory at the University of North Carolina Hospitals. Dr. Silverman is a diplomate of the American Board of Clinical Chemistry and a Fellow of the American College of Medical Genetics.



JOHN YATES III, PH.D.

The Ernest W. Hahn Professor in the Department of Chemical Physiology and Molecular & Cellular Neurobiology at The Scripps Research Institute, Dr. Yates is the lead inventor of the SEQUEST software for correlating tandem mass spectrometry data to sequences in the database and developer of the shotgun proteomics technique for analysis of protein mixtures. Dr. Yates was ranked by Citation Impact, Science Watch as one of the Top 100 Chemists for the decade, 2000-2010. Dr. Yates is the Editor in Chief at the Journal of Proteome Research.



STEVE ELLIOT, PH.D.

Recently retired from his Scientific Executive Director Position at Amgen, where he had worked since 1983, he continues to work in conjunction with the antidoping movement. During his early years at the company, he performed structure-function studies on erythropoietin and the erythropoietin receptor and is the inventor of Aranesp, a re-engineered analog of rHuEpo with a longer serum half-life. His discoveries played a key role in three crosscountry skiers being stripped of their gold medals and suspended from competition for two years following the 2002 Olympic Winter Games.



ANNETTE SALMEEN, PH.D.

Dr. Salmeen, D.Phil., was a 1996 Olympian and gold medalist. She served as an athlete's representative for the USA Swimming national governing body from 1996 to 2005. In 2005, she was elected as an athlete member of the U.S. Anti-Doping Agency Board of Directors and served until 2012. She was a member of the USADA board research committee and was also involved with efforts to support athlete education and the USADA True Sport initiative. She earned her doctoral degree in Biochemistry as a Rhodes Scholar at Oxford in 2001 and studied growth factor signalling pathways as a post-doctoral fellow in the Chemical and Systems Biology department at Stanford. She is currently a lecturer in the Human Biology Program at Stanford.



2016: A YEAR IN REVIEW



2016 AT A GLANCE

\$2.7 M USD

AWARDED WORLDWIDE

Representing a 40% increase in USD over funding in 2015. Total number of awards was increased by 75%.

21

SCIENTISTS (& THEIR TEAMS) SUPPORTED

Through PCC Grants, Micro-Grants, Working Groups, Center of Excellence Grants, and/or Fellowships.

57%

INTERNATIONAL AWARDS

The PCC provided 16 of 28 awards to investigators conducting research outside of the US.

43


RESEARCH OUTPUTS

Publications and presentations directly resulting from PCC funded research.

FUNDING FACTS AND FIGURES


2016 FUNDING BY PROJECT CATEGORY

As a percentage of total awards, not including Working Groups.




2016 AWARDS BY FUNDING MECHANISM

As a percentage of total awards.



GLOBAL REACH

The PCC funded 21 unique investigators representing eight different countries. The accompanying numbers represent total awards per country.



GRANTS APPROVED

Grants

63% of total USD awarded

Application of Dried Blood Spots in the Detection of Insulin and Testosterone Ester. Dr. Nikolai Nordsborg, University of Copenhagen. (DE)

Exhaled Breath in Doping Controls: Method Expansion, Optimization, Detection Window Determination. Dr. Mario Thevis, German Sport University. (DE)

Characterization of Low Temperature Catalytic Combustion Reactors for Steroids in Fast GC-C-IRMS. Dr. Herbert Tobias, Dell Pediatric Institute. (US)

Sensitive and Quick Detection of PEDs Using Microtoroid Optical Resonators. Dr. Judith Su, University of Arizona. (US)

Androgen Monitoring of Amateur and Young Athletes. Dr. Fred Schaufele, X-Cell Assay. (US)

Development of a Capillary-Electrophoresis Method for Detection of Recombinant Erythropoietins. Dr. Phillipe Desharnais, IRNS Sante. (CA)

Evaluating Erthroferrone as a New Marker of Erthropoesis Stimulators Abuse. Dr. Gaetano Cairo, University of Milan. (IT)

Rapid Detection of Performance Enhancing Drugs Using Nanotechnology. Dr. Nico Voelcker, Monash University. (AU)

Real Time Screening for Novel Designer Drugs and Other Controlled Substances in Doping Control. Dr. James Harynuk, University of Alberta. (CA)

Rapid Detection of EPO Isoforms in Blood by Handheld Raman and Electrochemical Devices. Dr. Emad Kiriakous, Queensland University of Technology. (AU)

Purchase of Dried Blood Spot Automated Sampling Handler. SMRTL/UCLA (US)

Fellowship

5% of total USD awarded

A PCC Fellowship was granted to one applicant, Dr. Liying Jiang, who is currently working under Dr. David Cowan at the Drug Control Center at King's College London.

Working Groups

14% of total USD awarded

IGF-1 Working Group:

Dr. Anthony Butch, UCLA Olympic Lab. (US)
Dr. Mario Thevis, German Sport University. (DE)
Dr. Daniel Eichner, SMRTL. (US)
Dr. David Cowan, King's College London. (UK)
Dr. Andy Hoofnagle, University of Washington. (US)
Dr. Richard Holt, University of Southampton. (UK)
Dr. Larry Bowers, USADA (ret.). (US)

Hematology Working Group:

Dr. John Higgins, Massachusetts General Hospital. (US)
Dr. Daniel Eichner, SMRTL. (US)
Dr. James McClung, USARIEM. (US)
Dr. Larry Bowers, USADA (ret.). (US)
Dr. Mike Sawka, Georgia Institute of Technology. (US)

Micro-Grants

18% of total USD awarded

Exhaled Breath as a Potential Alternative Matrix in Doping Controls: A Pilot Study. Dr. Mario Thevis, German Sport University. (DE)

Testosterone Codeine Interaction Study. Dr. Lena Ekstrom, Karolinska Institutet. (SE)

Mildronate Pilot Excretion Study. Dr. Mario Thevis, German Sport University Cologne. (DE)

Reference Materials of Long-Term Metabolite of Oral-Turinabol. Dr. Maria Parr, Freie Universität Berlin. (DE)

Conversion of the Hematologic Passport Testing for Use with Dried Blood Spots. Dr. Daniel Eichner, SMRTL. (US)

Urine Steroid Profile in Testosterone-Treated Female-to-Male (F2M) Transgender Men. Dr. David Handelsmann, Anzac Institute. (AU)

Novel Low Temperature Catalytic Combustion Reactors for Fast GCC/IRMS. Dr. Herbert Tobias, Dell Pediatric Institute (Research performed at Cornell University). (US)

DPS Card Manufacturing. Dr. Jack Henion, Q2 Solutions. (US)

Administration of Clomiphene: Short and Long Term Metabolism in an Anti-Doping Setting. Dr. Daniel Eichner, SMRTL. (US)

PUBLICATIONS

Authors A-K

Agoston, R., Izake, Emad L., Sivanesan, Arumugam, Lott, William B., Sillence, Martin, Steel, Rohan. Rapid Isolation and Detection of Erythropoietin in Blood Plasma by Magnetic Core Gold Nanoparticles and Portable Raman Spectroscopy. Nanomedicine. 12 (3): 633–641. DOI: <http://dx.doi.org/10.1016/j.nano.2015.11.003>, 2016.

Bailey, K., Yazdi, T., Masharani U., Tyrrell B., Butch A., Schaufele F. Advantages and Limitations of Androgen Receptor-Based Methods for Detecting Anabolic Androgenic Steroid Abuse as Performance Enhancing Drugs. PLoS One. 11(3):e0151860. DOI: 10.1371/journal.pone.0151860, 2016.

Bejder, J., Hoffmann, M. F., Ashenden, M., Nordsborg, N. B., Karstoft, K., and Mørkeberg, J. Acute Hyperhydration Reduces Athlete Biological Passport OFF-hr Score. Scandanavian J Med Sci Sports. 26, 338–347. DOI:10.1111/sms.12438, 2016.

Böhning, D., Böhning, W., Guha, N., Cowan, D., Sönksen, P., and Holt, R.I.G. Statistical Methodology for Age-Adjustment of the GH-2000 Score Detecting Growth Hormone Misuse. BMC Medical Research Methodology. 16 (147). DOI: 10.1186/s12874-016-0246-8, 2016.

Butch, A. W., and Woldemariam, G. A. Urinary Human Chorionic Gonadotropin Isoform Concentrations in Doping Control Samples. Drug Testing and Analysis. 8, 1147–1151. DOI: 10.1002/dta.2061, 2016.

Elbe, A., Jensen, N., Elsborg, P., Wetzke, M., Woldemariam, G., Huppertz, B., Keller, R., Butch, A. The Urine Marker Test: An Alternative Approach to Supervised Urine Collection for Doping Control, Sports Medicine. 46 (1): 15–22. DOI: 10.1007/s40279-015-0388-6, 2016.

Ellefsen, K.E., Concheiro, M., Pirard, S., Gorelick, D.A., Huestis M.A. Pharmacodynamic Effects and Relationships to Plasma and Oral Fluid Pharmacokinetics after Intravenous Cocaine Administration. Drug Alcohol Dependence. 1;163, 116–25. DOI: 10.1016/j.drugalcdep.2016.04.004, 2016.

Ellefsen K.E., Concheiro, M., Pirard, S., Gorelick D.A., Huestis, M.A. Cocaine and Benzoyllecgonine Oral Fluid On-Site Screening and Confirmation. Drug Testing and Analysis. 8(3-4), 296–303. DOI: 10.1002/dta.1966, 2016.

Ellefsen, K.E., Concheiro, M., Pirard, S., Gorelick, D.A., Huestis, M.A. Oral Fluid Cocaine and Benzoyllecgonine Concentrations Following Controlled Intravenous Cocaine Administration. Forensic Science International. 260, 95–101. DOI: 10.1016/j.forsciint.2016.01.013, 2016.

Geldof, L., Deventer, K., Tudela, E., and Van Eenoo, P. In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011. International Journal of Molecular Sciences. 17(10), 1676. DOI: 10.3390/ijms17101676, 2016.

Geldof, L., Tudela, E., Lootens, L., van Lysebeth, J., Meuleman, P., Leroux-Roels, G., van Eenoo, P., and Deventer, K. In Vitro and In Vivo Metabolism Studies of Dimethazine. Biomedical Chromatography. 30, 202–1209, DOI: 10.1002/bmc.3668., 2016.

Grau, M., Friederichs, P., Krehan, S., Koliymitra, C., Suhr, F., Bloch, W. Decrease in Red Blood Cell Deformability is Associated with a Reduction in RBCNOS Activation During Storage. Clinical Hemorheology and Microcirculation. 60 (2): 215–229. DOI: 10.3233/CH-141850, 2016.

Holt, R.I.G., Guha, N., Böhning, W., Bartlett, C., Cowan, D.A., Sönksen, P.H., and Böhning, D. Novel Markers to Detect Recombinant Human Insulin-Like Growth Factor-I (rhIGF-I)/rhIGF Binding Protein-3 (rhIGFBP-3) Misuse in Athletes. Drug Testing and Analysis. Epub. DOI: 10.1002/dta.1941, 2016.

Knoop, Andre, Thomas, Andreas, Fichant, Eric, Delahaut, Philippe, Schänzer, Wilhelm, Thevis, Mario. Qualitative Identification of Growth Hormone-Releasing Hormones in Human Plasma by Means of Immunoaffinity Purification and LC-HRMS/MS. Analytical and Bioanalytical Chemistry. 408: 3145–3153. DOI: 10.1007/s00216-016-9377-3, 2016.

PUBLICATIONS

Authors M-Z

Martin, L., Ashenden, M., Bejder, J., Hoffmann, M., Nordsborg, N., Karstoft, K., Morkeberg, J., Sharpe, K., Lasne, F., and Marchand, A. New Insights for Identification of Doping with Recombinant Human Erythropoietin Micro-Doses After High Hydration. *Drug Testing and Analysis*. 8 (11-12), 1119–1130. DOI: 10.1002/dta.2004, 2016.

Miller G.D., Nair, V., Morrison M., Summers M., Willick S.E., Eichner D. Intranasal Delivery of Natesto® Testosterone Gel and its Effects on Doping Markers. *Drug Testing And Analysis*. 8 (11-12), 1197-1203. DOI: 0.1002/dta.2106, 2016.

Mullen, J. E., Thörngren, J.O., Schulze, J. J., Ericsson, M., Gårevik, N., Lehtihet, M., and Ekström, L. Urinary Steroid Profile in Females – the Impact of Menstrual Cycle and Emergency Contraceptives. *Drug Testing and Analysis*. Epub. DOI: 10.1002/dta.2121, 2016.

Musrap, N., and Diamandis, E.P. Prostate-Specific Antigen as a Marker of Hyperandrogenism in Women and Its Implications for Antidoping. *Clinical Chemistry*. 62 (8), 1066-1074. DOI: 10.1373/clinchem.2016.256198, 2016.

Nerenz R.D., Butch A.W., Woldemariam G.A., Yarbrough M., Grenache D.G., Gronowski A.M. Estimating the hCG β cf in Urine During Pregnancy. 49(3), 282-6. DOI: 10.1016/j.clinbiochem.2015.10.020, 2016.

Polet, M., Van Gansbeke, W., Van Eenoo, P., Deventer, K. Gas Chromatography/Chemical Ionization Triple Quadrupole Mass Spectrometry Analysis of Anabolic Steroids: Ionization and Collision-Induced Dissociation Behavior. *Rapid Communications in Mass Spectrometry*. 30, 511-12, DOI: 10.1002/rcm.7472., 2016.

Polet, M., Van Gansbeke, W., Van Eenoo, P., Deventer, K. Efficient Approach for the Detection and Identification of New Androgenic Metabolites by Applying SRM GC-CI-MS/MS: a Methandienone Case Study. *Journal of Mass Spectrometry*. 51, 524-34, DOI: 10.1002/jms.3781, 2016.

Ryona, I., and Henion, J. A Book-Type Dried Plasma Spot Card for Automated Flow-Through Elution Coupled with Online SPE-LC-MS/MS Bioanalysis of Opioids and Stimulants in Blood. *Analytical Chemistry*. 88 (22), 11229–11237, DOI: 10.1021/acs.analchem.6b03691, 2016.

Salamin, O., De Angelis, S., Tissot, J.D., Saugy, M., Leuenberger, N. Autologous Blood Transfusion in Sports: Emerging Biomarkers. *Transfusion Medicine Reviews*. 30 (3), 109–115. DOI: 10.1016/j.tmr.2016.05.007, 2016.

Thoren, Katie L., Colby, Jennifer M., Shugarts, Sarah B., Wu, Alan H.B., Lynch, Kara L. Comparison of Information-Dependent Acquisition on a Tandem Quadrupole TOF vs a Triple Quadrupole Linear Ion Trap Mass Spectrometer for Broad-Spectrum Drug Screening. *Clinical Chemistry*. 62 (1), 170-178, DOI: 10.1373/clinchem.2015.241315, 2016.

Tretzel, L., Görgens, C., Geyer, H., Thomas, A., Dib, J., Guddat, S., Pop, S., Schänzer, W., Thevis, M. Analyses of Meldonium (Mildronate) from Blood, Dried Blood Spots (DBS), and Urine Suggest Drug Incorporation into Erythrocytes. *International Journal of Sports Medicine*. 37(06), 500 – 502. DOI: 10.1055/s-0036-1582317, 2016.

Verplaetse, R., and Henion, J. Hematocrit-Independent Quantitation of Stimulants in Dried Blood Spots: Pipet versus Microfluidic-Based Volumetric Sampling Coupled with Automated Flow-Through Desorption and Online Solid Phase Extraction-LC-MS/MS Bioanalysis. *Anal Chem*, Jul 5;88(13), 6789-96. DOI: 10.1021/acs.analchem.6b01190, 2016.

Verplaetse, R., and Henion, J. Quantitative Determination of Opioids in Whole Blood Using Fully Automated Dried Blood Spot Desorption Coupled to On-line SPE-LC-MS/MS. *Drug Testing And Analysis*. 8, 30–38. DOI: 10.1002/dta.1927, 2016.

Willick, S.E., Miller, G.D., Eichner, D. The Anti-Doping Movement. *PM&R*. Mar;8(3 Suppl), S125-32. DOI: 10.1016/j.pmrj.2015.12.001, 2016.

PRESENTATIONS

Colby, J.M. New Library Search Algorithm Improves Identification of Drugs by LC-QqTOF. Mass Spectrometry: Applications to the Clinical Laboratory Conference. 2016. Palm Springs, USA.

Cowan, D., Galesio, M., Gavrilovic. Identification of Growth Hormone Releasing Hormones in Human Plasma by Means of Immunoaffinity Purification and LC-HRMS/MS. 34th Cologne Workshop on Doping Analysis. 2016. Cologne, Germany.

Cowan, D. Towards Quantifying PIIINP in Human Serum by LC-MS: Separating PIIINP from Human Serum Albumin. Analytical and Environmental Sciences Division Symposium, King's College London. 2016. London, United Kingdom.

Geldof, L., Deventer, K., Tudela, E., and Van Eenoo P. In Vitro Metabolism Studies of REV-ERB α Agonists SR9009 and SR9011. 34th Manfred Donike Workshop on Doping Analysis. 2016. Cologne, Germany.

Gonçalves, A., Salema, B., Ruivo, J., Ramos, S., Luz, S., Chapman, T., and Aguilera, R. Development and Validation of a Methodology for the Detection of Synthetic Forms of Endogenous Anabolic Androgenic Steroids in Urine Samples by GC-C-IRMS. XVI Latino-Americano Conference on Chromatography. 2016. Lisbon, Portugal.

Henion, J., Ryona, I. New Microsampling Hematocrit-Compatible Dried Plasma Card for Fully Automated On-Line DBSA-SPE-LC/MS/MS Bioanalysis of Opioids in Blood. 2016 American Society for Mass Spectrometry Conference. 2016. San Antonio, USA.

Lynch, K.L. High Resolution Mass Spectrometry for Suspect Screening of Novel Psychoactive Substances: Is it a Viable Solution for Laboratories. Mass Spectrometry: Applications to the Clinical Laboratory Conference. 2016. Palm Springs, USA.

Lynch, K.L. Analytical Advances in Clinical Toxicology Using High Resolution Mass Spectrometry. Yale University, Department of Laboratory Medicine Research Conference Series. 2016. New Haven, USA.

Lynch, K.L. Q-TRAP or Q-TOF for Comprehensive Drug Screening? Analytical World Conference/Society of Toxicological and Forensic Chemistry. 2016. Munich, Germany.

Miller, G., Teramoto, M., Cushman, D., Eichner, D. Assessing Dehydration in the Context of the Biological Passport. 34th Cologne Workshop on Doping Analysis. 2016. Cologne, Germany.

Nair, V., Miller, G., Morrison, S., Summers, M., Willick, S., Eichner, D. Intranasal Delivery of Natesto Testosterone Gel and Its Effects on Doping Markers. 34th Cologne Workshop on Doping Analysis. 2016. Cologne, Germany.

Polet, M., Van Gansbeke, W., and Van Eenoo, P. Chemical Ionization GC-MS/MS Analysis of Anabolic Androgenic Steroids. 34th Cologne Workshop on Doping Analysis. 2016. Cologne, Germany.

Thevis, M. Qualitative Identification of Growth Hormone-Releasing Hormones in Human Plasma by Means of Immunoaffinity Purification and LC-HRMS/MS. 34th Cologne Workshop on Doping Analysis. 2016. Cologne, Germany.

Tobias, H.J., Brenna, J.T. Cryogenic-Focusing Fast Gas Chromatography Isotope Ratio Mass Spectrometry. 64nd ASMS Conference on Mass Spectrometry and Allied Topics. 2016. San Antonio, USA.

Van Eenoo, P., Polet, M. Chemical Ionization GC-MS/MS Analysis of Anabolic Androgenic Steroids. Agilent Nordic Scientific Forum. 2016. Gothenburg, Sweden.



FINANCIAL OVERVIEW



Financial Statements and Report of Independent
Certified Public Accountants

**Partnership for Clean Competition
Research Collaborative**

December 31, 2016 and 2015

Contents

	Page
Report of Independent Certified Public Accountants	2
Statements of financial position	4
Statements of activities	5
Statements of cash flows	6
Notes to financial statements	7



Report of Independent Certified Public Accountants

Grant Thornton LLP
1801 California Street, Suite 3700
Denver, CO 80202
T 303.813.4000
F 303.839.5711
www.GrantThornton.com

The Board of Governors of the
Partnership for Clean Competition Research Collaborative:

We have audited the accompanying financial statements of the Partnership for Clean Competition Research Collaborative ("PCC"), which comprise the statements of financial position as of December 31, 2016 and 2015, and the related statements of activities and cash flows for the years then ended, and the related notes to the financial statements.

Management's responsibility for the financial statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Partnership for Clean Competition Research Collaborative as of December 31, 2016 and 2015, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

/s/ Grant Thornton LLP

Denver, Colorado
May 8, 2017

Statements of financial position

	As of December 31,	
	2016	2015
Assets		
Cash and cash equivalents	\$ 4,730,945	\$ 5,347,096
Restricted cash	1,759,978	2,000,000
Pledges receivable, net	742,034	100,000
Prepaid expenses	15,616	3,867
Prepaid fellowship	71,875	21,875
Software, net	138,086	139,825
Total assets	<u>\$ 7,458,534</u>	<u>\$ 7,612,663</u>
Liabilities and net assets		
Liabilities		
Accounts payable and accrued liabilities	\$ 117,269	\$ 43,550
Grants payable	104,131	809,450
Total liabilities	<u>221,400</u>	<u>853,000</u>
Net assets		
Unrestricted	5,995,100	6,159,663
Temporarily restricted	1,242,034	600,000
Total net assets	<u>7,237,134</u>	<u>6,759,663</u>
Total liabilities and net assets	<u>\$ 7,458,534</u>	<u>\$ 7,612,663</u>

The accompanying notes are an integral part of these financial statements.

Statements of activities

	Year ended December 31, 2016			Year ended December 31, 2015		
	Unrestricted	Temporarily restricted	Total	Unrestricted	Temporarily restricted	Total
Support and revenue						
Contributions	\$ 2,500,000	\$ 992,034	\$ 3,492,034	\$ 2,503,148	\$ 500,000	\$ 3,003,148
Other	291		291	16,042	-	16,042
Net assets released from restrictions	350,000	(350,000)	-	96,852	(96,852)	-
Total support and revenue	2,850,291	642,034	3,492,325	2,616,042	403,148	3,019,190
Expenses						
Program services						
Anti-doping research	2,688,923	-	2,688,923	2,355,232	-	2,355,232
Total program services	2,688,923	-	2,688,923	2,355,232	-	2,355,232
Supporting services						
Fundraising	25,142	-	25,142	16,992	-	16,992
General and administrative	300,789	-	300,789	229,365	-	229,365
Total supporting services	325,931	-	325,931	246,357	-	246,357
Total expenses	3,014,854	-	3,014,854	2,601,589	-	2,601,589
Changes in net assets	(164,563)	642,034	477,471	14,453	403,148	417,601
Net assets, beginning of period	6,159,663	600,000	6,759,663	6,145,210	196,852	6,342,062
Net assets, end of period	<u>\$ 5,995,100</u>	<u>\$ 1,242,034</u>	<u>\$ 7,237,134</u>	<u>\$ 6,159,663</u>	<u>\$ 600,000</u>	<u>\$ 6,759,663</u>

The accompanying notes are an integral part of these financial statements.

Statements of cash flows

	Years ended December 31,	
	2016	2015
Operating activities		
Change in net assets	\$ 477,471	\$ 417,601
Adjustments to reconcile changes in net assets to net cash (used in) provided by operating activities		
Amortization	37,008	29,660
Changes in assets and liabilities		
(Increase) decrease in pledges receivable	(642,034)	96,852
Increase in prepaid expenses and prepaid fellowship	(61,749)	(11,823)
Increase (decrease) in accounts payable and accrued liabilities	73,719	(16,577)
(Decrease) increase in grants payable	(705,319)	671,782
Net cash (used in) provided by operating activities	(820,904)	1,187,495
Investing activities		
Change in restricted cash	240,022	(2,000,000)
Purchase of software	(35,269)	(78,000)
Net cash provided by (used in) investing activities	204,753	(2,078,000)
Net decrease in cash and cash equivalents	(616,151)	(890,505)
Cash and cash equivalents, beginning of year	5,347,096	6,237,601
Cash and cash equivalents, end of year	\$ 4,730,945	\$ 5,347,096

The accompanying notes are an integral part of these financial statements.

Notes to financial statements

Note A – Summary of significant accounting policies

Organization

The Partnership for Clean Competition Research Collaborative (“PCC”) was established on February 21, 2008 as a not-for-profit organization established under IRC Section 501(c)(3) with the United States Olympic Committee (“USOC”) as the sole IRC Section 501(c)(3) member. PCC’s mission is to protect the integrity of sport and public health by engaging and supporting the world’s top scientists and innovators in high-quality anti-doping research and development. By combining the resources and expertise of America’s leading sports entities, the PCC supports non-partisan and independent scientific research by fundraising and making targeted grants to various universities and other world-class research institutions. This independent research primarily focuses on developing more effective tests for performance-enhancing substances, the societal causes of doping, and non-test based methods to decrease doping and performance-enhancing drug use across all levels of athletic participation and competition, from the casual youth sports participant to the elite amateur and professional athlete. The PCC also facilitates adoption of these methods into the World Anti-Doping Agency accredited laboratories.

The PCC is governed under the direction of a Board of Governors consisting of three constituent classes of members: one class of members is comprised of USOC representatives; one class of members is comprised of representatives from professional sports leagues, unions of professional athletes and/or other individuals that make demonstrated, long-term economic commitments in support of the PCC; the final class of members is comprised of a representative from the United States Anti-Doping Agency.

The PCC board is supported by a Scientific Research Advisory Board, who independently reviews the relative merits of particular research projects and makes recommendations to the Board of Governors as to appropriate areas and subjects for making scientific research grants. This advisory body is comprised of members who are universally-recognized experts in their field or scientific expertise, individuals from academia, individuals from the public health sector and/or individuals who otherwise represent the public interest.

The Executive Director of the PCC oversees the day-to-day administration of the organization and reports directly to the Board of Governors.

December 31, 2016 and 2015

Note A – Summary of significant accounting policies (continued)

Contributions

Contributions represent unconditional cash donations and future pledges of cash donations from the organizations represented on the Board of Governors, as well as donations from the general public. The PCC reports contributions of cash and other assets as temporarily or permanently restricted contributions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or the donor stipulations have been met, temporarily restricted net assets are reclassified to unrestricted net assets and reported as net assets released from restrictions in the statement of activities. Contributions of cash and other assets that are originally restricted by the donor and for which the restriction is met in the same time period are recorded as unrestricted.

Unconditional promises to give the PCC cash in the future or over a period spanning multiple years are recorded as temporarily restricted net assets at the estimated fair value when the pledge is made. Fair value is determined by computing the present value of future cash flows discounted at the risk-free interest rate as of the period in which the agreement was received, adjusted for any associated credit risks. As cash donations are received under the pledge, temporarily restricted net assets are reclassified to unrestricted net assets and reported as net assets released from restrictions in the statement of activities.

Cash and cash equivalents

Cash and short term investments with original maturities of three months or less from the date of acquisition are considered cash and cash equivalents. As of December 31, 2016 and 2015, all cash and cash equivalents represent demand deposits.

Restricted cash

Restricted cash of \$1,759,978 and \$2,000,000 as of December 31, 2016 and 2015, respectively, consists of cash held in custody of the World Anti-Doping Agency (WADA) that is restricted for funding PCC anti-doping research grants in partnership with WADA.

Pledges receivable

Pledges receivable, net of an annual discount of 1.41%, are deemed fully collectible as of December 31, 2016 and 2015. Pledges are due to be collected over the coming years in the following amounts:

	As of December 31, 2016
Year ending December 31,	
2017	\$ 370,683
2018	122,377
2019	124,095
2020	124,879
	<u>\$ 742,034</u>

For the years ended December 31, 2016 and 2015, \$0 and \$3,148, respectively, of the pledge discount was amortized into contribution revenue. As of December, 31, 2016 and 2015, the unamortized pledge discount was \$7,966 and \$0, respectively.

December 31, 2016 and 2015**Note A – Summary of significant accounting policies (continued)****Software**

Costs of computer software developed or obtained for internal use are recorded in accordance with Accounting Standards Codification (ASC) Topic 350. Under Topic 350, costs incurred during the preliminary project stage are expensed as incurred, costs incurred during the application development stage are capitalized and training and maintenance costs incurred during the post-implementation / operation stage are expensed as incurred. Amortization of software is provided on the straight-line method over an estimate useful life of 5 years.

Software is reported net of accumulated amortization of \$71,483 and \$34,475 as of December 31, 2016 and 2015, respectively.

Grants payable

The PCC awards targeted grants to research institutions each year in order to fund independent scientific research projects aimed at increasing detection and prevention of performance-enhancing substance use in professional and amateur sports. The research projects generally extend over a period of one to three years. The liability is recorded as grants payable in the statement of financial position and the associated expense is recorded as drug research expense in the statement of activities when the grant agreements are executed by the PCC.

Federal income taxes

The PCC is exempt from federal and state income taxes on income from activities related to its exempt purposes under IRC Section 501(a) of the Internal Revenue Code as an organization described in IRC Section 501(c)(3). The PCC had no unrelated business income for the periods ended December 31, 2016 and 2015.

Net assets

For financial reporting purposes, resources are classified into net asset categories according to the existence or absence of donor imposed restrictions. Accordingly, net assets of the PCC and changes therein are classified and reported as follows:

- Unrestricted net assets – Net assets that are not subject to donor-imposed stipulations.
- Temporarily restricted net assets – Net assets that are subject to donor-imposed stipulations that may or will be met either with actions of the PCC and/or the passage of time. When a restriction expires, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities as net assets released from restrictions.

December 31, 2016 and 2015

Note A – Summary of significant accounting policies (continued)

Net assets (continued)

The PCC has adopted the *Uniform Prudent Management of Institutional Funds Act* (“UPMIFA”) passed by the state of Colorado. In accordance with UPMIFA, the PCC appropriates for expenditure or accumulates as much of an endowment fund as the PCC determines is prudent for the uses, benefits, purposes or duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument. As of December 31, 2016 and 2015, the PCC has no board-designated or donor restricted endowment funds.

Functional expenses

The cost of providing supporting services has been summarized on a functional basis in the statement of activities. Certain costs have been allocated among the supporting services benefited based on labor dollars or costs incurred.

Management estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions. Such estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.

Uncertain tax positions

As required by the uncertain tax position guidance, the PCC recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The adoption of this guidance did not have a material effect on the Company’s financial statements.

Recently adopted standards

PCC management has evaluated the most recent framework for measuring fair value and concluded that the PCC does not have assets or liabilities recognized in the financial statements measured at fair value on a recurring basis. Accordingly, management concluded the adoption of related guidance did not have a significant impact on its results of operations, financial position, or note disclosures.

Note B – Service agreement

The PCC has a service agreement with the USOC where the USOC has agreed to make available to the PCC various services including the Executive Director, legal services, accounting services, communications and public relations, information technology and human resources. The PCC is obligated to reimburse the USOC for these services, which have been calculated at the USOC’s cost. The Executive Director’s services are billed to the PCC for actual labor, benefits and payroll tax costs incurred. Legal and accounting services are billed to the PCC at a fixed monthly rate. Information technology, human resources and communication services are reimbursed to the USOC based on an hourly rate for services performed. For the years ended December 31, 2016 and 2015, the amount PCC incurred from the USOC for these services was \$278,418 and \$186,179, respectively.

December 31, 2016 and 2015

Note C – Subsequent events

The PCC has evaluated subsequent events through the date that the financial statements were available to be issued on May 8, 2017. Management was not aware of any subsequent events which would require recognition or disclosure in the financial statements.



© Grant Thornton LLP
All rights reserved
U.S. member firm of Grant Thornton International Ltd

This report is confidential. Unauthorized use of this report in whole or in part is strictly prohibited.

PARTNERSHIP FOR
clean competition

CLEANCOMPETITION.ORG

STAY CONNECTED



/PCCANTIDOPING

FOUNDING PARTNERS



CONTRIBUTORS

